Drug Trial Radar · NCT07902830
A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 30, 2029
Study completion Jan 30, 2029
Sponsor
- Lead sponsor
- X4 PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of G-CSF dosage reduction with mavorixafor in participants with autoimmune neutropenia (AIN) and chronic idiopathic neutropenia (CIN) disorders as assessed by the ability to safely reduce G-CSF dosage with mavorixafor treatment while maintaining clinically acceptable absolute neutrophil count (ANC) levels.
Conditions
- Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
- Chronic Neutropenia
- Autoimmune Neutropenia
- Chronic Idiopathic Neutropenia
Interventions
MavorixaforDrug
Mavorixafor will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Week 56
- Percent Change in Average Daily G-CSF DosageTime frame: Week 12 through Week 28 or 32
- Percentage of Participants Achieving G-CSF CessationTime frame: Week 28 or 32
- Percentage of Participants Achieving G-CSF Dosage Reduction ≥75%Time frame: Week 28 or 32
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.